Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
Psychiatric and neurological disorders
According to the World Health Organization, WHO, more than 700 million people lives with psychiatric and neurological disorders globally. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives.
As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics.
Research and development
Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have a state-of-the-art research facility in Denmark, and more than 800 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions.
Lundbeck markets a number of different pharmaceuticals for the treatment of psychiatric and neurological disorders. The most recently launched compounds include: Rexulti® (depression and schizophrenia), Brintellix® (depression) and Abilify Maintena® (schizophrenia).
Lundbeck employs approximately 5,000 people worldwide. We have employees in more than 50 countries, and our products are registered in more than 100 countries. We have production facilities in Denmark, France and Italy and our research centre is based in Denmark. Lundbeck generated revenue of approximately DKK 17.2 billion in 2017.
Lundbeck’s Executive Management consists of six members, headed by Deborah Dunsire, President & CEO.
In 2017, 17% of our revenue derived from Europe, 63% from the North America and 20% from the International Markets region.
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies. During the past century, millions of people have been treated with our therapies. It is complex and challenging to develop improved treatments for psychiatric and neurological disorders, but we keep our focus in order to ensure a better life for people living with psychiatric and neurological disorders.
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which annually distributes around 400-500 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.
Progress in Mind
Progress in Mind is Lundbeck’s dedication to addressing the global burden of brain disease.Learn more on our corporate website